AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca is conducting a phase 1 clinical study titled A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects With B-Cell Non-Hodgkin Lymphoma. The study aims to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of AZD0486 in patients with B-cell non-Hodgkin lymphoma.
The intervention being tested is AZD0486, a bispecific antibody designed to engage T-cells and target CD19 on tumor cells, facilitating T cell-mediated destruction of malignant B cells. It is administered intravenously in a structured dosing schedule.
This interventional study follows a sequential intervention model with no masking, focusing primarily on treatment. Participants receive increasing doses of AZD0486, with safety and efficacy monitored throughout the study.
The study began on March 2, 2021, and is currently recruiting. The last update was submitted on July 22, 2025. These dates are crucial for tracking the study’s progress and ensuring timely updates to stakeholders.
The ongoing study may influence AstraZeneca’s stock performance and investor sentiment, as successful outcomes could enhance the company’s oncology portfolio. Investors should also consider the competitive landscape in the B-cell lymphoma treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.